AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Expanded agreement includes development of additional transgenic mouse technologies and performance of additional therapeutic antibody research programs
扩大的协议包括开发其他转基因小鼠技术和实施其他治疗性抗体研究项目
FOSTER CITY, CA / ACCESSWIRE / October 31, 2024 / AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the expansion of a previous agreement with Gilead Sciences, Inc. (Nasdaq:GILD) to develop novel antibody discovery technologies and discover therapeutic antibodies for Gilead-selected targets.
加利福尼亚州福斯特城/ACCESSWIRE/2024年10月31日/拥有创新技术的生物技术公司AbtherX今天宣布扩大先前与吉利德科学公司(纳斯达克股票代码:GILD)达成的协议,该协议旨在开发新的抗体发现技术,为吉利德选定的靶标发现治疗性抗体。
Under the initial agreement in June 2023, AbTherx received worldwide rights to Atlas Mice, a suite of transgenic mouse technologies acquired by Gilead, and committed to a multi-year, multi-target research collaboration. In just over a year, AbTherx established a world-class research center and successfully developed transgenic mouse technologies that express the full diversity of human antibody HC and k-LC repertoires and enable the development of bispecific antibodies through a novel binary fixed light chain. AbTherx is also continuing development of a technology that uses natural mechanisms to generate long CDRH3 antibodies to address challenging drug targets (e.g., GPCRs and ion channels) that was part of the original agreement. Under the expanded agreement, AbTherx will develop and receive worldwide rights to additional transgenic technologies and broaden the multi-year, multi-target research collaboration to include the performance of additional therapeutic antibody research programs.
根据2023年6月的初始协议,AbtherX获得了吉利德收购的一系列转基因小鼠技术Atlas Mice的全球版权,并承诺进行为期多年的多目标研究合作。在短短一年多的时间里,AbtherX建立了世界一流的研究中心,成功开发了转基因小鼠技术,这些技术表达了人类抗体HC和k-lc库的全部多样性,并允许通过新的二元固定轻链开发双特异性抗体。AbtherX 还在继续开发一项技术,该技术利用自然机制生成长 CDRH3 抗体,以应对具有挑战性的药物靶标(例如 GPCR 和离子通道),这是最初协议的一部分。根据扩大的协议,AbtherX将在全球范围内开发和获得更多转基因技术的使用权,并扩大为期多年的多目标研究合作,将其他治疗性抗体研究项目的实施包括在内。
"Having successfully developed multiple novel and innovative antibody discovery technologies under the original agreement, we are excited to expand our partnership with Gilead to include additional technologies and multiple new research programs," said Justin Mika, Chief Executive Officer of AbTherx. "This expanded partnership will strengthen our innovative portfolio of transgenic mouse technologies for therapeutic antibody discovery. We look forward to further developing these innovative technologies for use by Gilead and the broader biopharma community."
AbtherX首席执行官贾斯汀·米卡表示:“根据最初的协议,我们成功开发了多种新型和创新的抗体发现技术,我们很高兴扩大与吉利德的合作伙伴关系,将更多技术和多个新的研究项目包括在内。”“这种扩大的合作伙伴关系将加强我们用于治疗性抗体发现的转基因小鼠创新技术组合。我们期待进一步开发这些创新技术,供吉利德和更广泛的生物制药界使用。”
About AbTherx
关于 AbtherX
AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit .
AbtherX 正在通过革命性技术推动医学发展,这些技术可以加速和促进治疗性抗体的发现。通过吉利德科学的独家许可,AbtherX发布了Atlas Mice,这是一套新的转基因技术,旨在实现无与伦比的性能和操作自由度。20多年来,AbtherX的核心科学家团队共同努力突破抗体发现技术的界限,成功开展了1,000多项发现活动并开发了13种上市疗法。AbtherX 行业领先的团队创造了变革性解决方案,以克服在交付创新药物方面最严峻的挑战。AbtherX 致力于让所有人都能使用其技术,提供灵活的合作模式,以满足各种规模的药物开发商的需求。欲了解更多信息,请访问。
Media Contact
媒体联系人
Stacey Borders
stacey@abtherx.com
Stacey Borders
stacey@abtherx.com
SOURCE: AbTherx, Inc
资料来源:abtherX, Inc.